Navigation Links
Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
Date:11/27/2007

ndidates in clinical development. In addition to iloperidone, Vanda is developing VEC- 162, a compound for the treatment of sleep and mood disorders which is currently in Phase III development for sleep disorders. Vanda's third product candidate in clinical development, VSF-173, is currently in Phase II development for the treatment of excessive sleepiness. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Note Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A)
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und LONDON ... , Ziel der Zusammenarbeit sind ... genomischer Daten aus Plasmaproben zur Steuerung von Therapien ... werden kann  Neuer Bluttest basiert auf ... und soll auf Rotor-Gene Q, einer Automationsplattform der ...
(Date:7/28/2014)... and LONDON , July 28, 2014 ... to create and commercialize companion diagnostic using genomic data ...  for non-small cell lung cancer patients  New ... test and is planned to run on Rotor-Gene Q, member of ... enabled by AstraZeneca master framework agreement adds to QIAGEN,s ...
(Date:7/28/2014)... 2014 CTI BioPharma Corp. (CTI) (NASDAQ and ... second quarter 2014 financial results on Monday, August 4, ... Following the announcement, members of the management team will ... and provide a general corporate update at 4:30 p.m. ... be obtained as follows: Monday, August 4 ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
...   New product launches are continually occurring across various ... to balance the dueling goals of containing costs and producing ... determining how much to invest, and how to best spend ... primary care launch is spent before during the launch ...
... this week,s 46th Annual Midyear Clinical Meeting and Exhibition ... Health launched BarCode360™ , a solution that supports ... timely and cost efficient to order medications and ensure ... bedside. ASHP has set a goal for ...
Cached Medicine Technology:Launch Spend Insights: Companies Now Invest More in Launch Year Than in Previous 3 Ramp-Up Years Combined 2Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 2Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 3
(Date:7/28/2014)... WA (PRWEB) July 28, 2014 According to ... Vkool.com, this is a comprehensive fitness guide that teaches men ... per week. , Vkool reveals in its review that ... discover:, Ways to gain the maximum ... to build muscle and avoid fat gain , ...
(Date:7/28/2014)... July 28, 2014 TherapySites, ... health professionals, announced today its affiliation with the ... This new relationship allows TherapySites to continue to extend ... benefits and promotional offers. , “There has been a ... today. With nearly 3 billion Internet users, it ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 CW4K was ... First Lady Michelle Obama and Partnership for a ... as they join the group's DrinkUP effort, ... water, more often. , The seven organizations added ... Nalgene® Outdoor Products, S’well Bottle, Santa Clara Valley Water ...
(Date:7/28/2014)... July 28, 2014 Footwear etc. is ... styles from Mephisto. With shoes, sandals, and boots that ... products continually provide handmade comfort shoes and ... women have come to rely on the superb value, ... Mephisto shoes and sandals contain the highest quality materials ...
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 ... beyond, many are looking to private exchanges. “Private ... the August 6 webinar from Atlantic Information Services, will ... insurers’ private exchange strategies for the future. , Barbara ... from PwC with extensive experience in the private exchange ...
Breaking Medicine News(10 mins):Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 3Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 2Health News:CannedWater4Kids (CW4K) Among Those Invited to the White House to Support First Lady Michelle Obama in Welcoming Seven New Organizations to DrinkUP 3Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 2Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 3Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2
... Bangladesh are exposed to unsafe levels of arsenic in their ... serious diseases, according to the World Health Organization (WHO). ... surface, many people in Bangladesh have installed deep wells to ... In recent years, farmers have begun using the deep, uncontaminated ...
... , ... on board a flight from London to Los Angeles helped stabilize a flight attendant who ... in Montreal to care for this victim. , ... (Vocus) May 28, 2010 -- Dr. Semira Bayati was onboard United Airlines flight ...
... inherited lymphedema associated with lymphatic function has been discovered ... researchers at the University of Pittsburgh Graduate School of Public ... the American Journal of Human Genetics . ... an accumulation of fluid in a blocked or damaged lymphatic ...
... deformed bone into place instead of breaking it, researchers ... new technique for the treatment of bunions appears to ... for standard invasive surgery. , The novel procedure -- ... the foot and ankle program and an assistant professor ...
... ... called the Hospital Charitable Service Awards, has been created to celebrate and encourage the ... ... A new national awards program, called the Hospital Charitable Service Awards , ...
... Online Brand ... ... Peltz Shoes has partnered with local SEO Tampa Fla., firm Bayshore Solutions to ... usability, overall sense of online purchase security and search engine optimization that followed best practices., , ...
Cached Medicine News:Health News:Scientists offer solutions to arsenic groundwater poisoning in southern Asia 2Health News:Scientists offer solutions to arsenic groundwater poisoning in southern Asia 3Health News:Scientists offer solutions to arsenic groundwater poisoning in southern Asia 4Health News:Orange County Plastic Surgeon Helps Stabilize Wounded Flight Attendant Requiring an Emergency Landing 2Health News:Orange County Plastic Surgeon Helps Stabilize Wounded Flight Attendant Requiring an Emergency Landing 3Health News:Pitt researchers discover gene mutation linked to lymphatic dysfunction 2Health News:New Bunion Procedure Aims to Replace Invasive Foot Surgery 2Health News:Nominations Sought for Charitable Hospital Programs that ‘Give Back' 2Health News:Nominations Sought for Charitable Hospital Programs that ‘Give Back' 3Health News:Local SEO Tampa Firm Bayshore Solutions Bring Revenue Results to Premier Online Shoe Store Peltz Shoes 2Health News:Local SEO Tampa Firm Bayshore Solutions Bring Revenue Results to Premier Online Shoe Store Peltz Shoes 3
Liquichek Blood Gas Plus E Control is an aqueous product used to monitor the measurement of pH, pCO2, pO2 and electrolytes. Available in four levels....
Liquichek CK/LD Isoenzyme Control features analytes used in cardiac profile testing and protein electrophoresis. Assayed for most methods including instruments, immunoinhibition kits and electrophore...
Meter Trax Control is a whole blood quality control that can be used for glucose, hemoglobin and hematocrit testing on point of care instruments....
Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....
Medicine Products: